22 research outputs found
A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization
There are few randomized trials comparing filgrastim and pegfilgrastim in peripheral blood stem cell mobilization (PBSCM). None of the trials studied the effects of the timing of pegfilgrastim administration on the outcomes of mobilization. We conducted a randomized triple blind control trial comparing the outcomes of filgrastim 5 microg/kg daily from day 3 onwards, 'early' pegfilgrastim 6 mg on day 3 and 'delayed' pegfilgrastim 6 mg on day 7 in cyclophosphamide PBSCM in patients with no previous history of mobilization. Peripheral blood (PB) CD34+ cell count was checked on day 8 and day 11 onward. Apheresis was started when PB CD34+ >/= 10/microl from day 11 onward. The primary outcome was the successful mobilization rate, defined as cumulative collection of >/=2 x 10(6)/kg CD34+ cells in three or less apheresis. The secondary outcomes were the day of neutrophil and platelet engraftment post transplantation. There were 156 patients randomized and 134 patients' data analyzed. Pegfilgrastim 6 mg day 7 produced highest percentage of successful mobilization, 34 out of 48 (70.8%) analyzed patients, followed by daily filgrastim, 28 out of 44 (63.6%) and day 3 pegfilgrastim, 20 out of 42 (47.6%) (p = 0.075). Pegfilgrastim day 7 and daily filgrastim reported 1.48 (p = 0.014) and 1.49 (p = 0.013) times higher successful mobilization rate respectively as compared to pegfilgrastim day 3 after adjusting for disease, gender and exposure to myelotoxic agent. Multiple myeloma patients were three times more likely to achieve successful mobilization as compared to acute leukemia or lymphoma patients. Pegfilgrastim avoided the overshoot of white cells compared to filgrastim. There was no difference in the duration of both white cells and platelet recovery post transplantation between the three interventional arms
The Liver Tumor Segmentation Benchmark (LiTS)
In this work, we report the set-up and results of the Liver Tumor
Segmentation Benchmark (LITS) organized in conjunction with the IEEE
International Symposium on Biomedical Imaging (ISBI) 2016 and International
Conference On Medical Image Computing Computer Assisted Intervention (MICCAI)
2017. Twenty four valid state-of-the-art liver and liver tumor segmentation
algorithms were applied to a set of 131 computed tomography (CT) volumes with
different types of tumor contrast levels (hyper-/hypo-intense), abnormalities
in tissues (metastasectomie) size and varying amount of lesions. The submitted
algorithms have been tested on 70 undisclosed volumes. The dataset is created
in collaboration with seven hospitals and research institutions and manually
reviewed by independent three radiologists. We found that not a single
algorithm performed best for liver and tumors. The best liver segmentation
algorithm achieved a Dice score of 0.96(MICCAI) whereas for tumor segmentation
the best algorithm evaluated at 0.67(ISBI) and 0.70(MICCAI). The LITS image
data and manual annotations continue to be publicly available through an online
evaluation system as an ongoing benchmarking resource.Comment: conferenc